Anzeige
Mehr »
Sonntag, 26.10.2025 - Börsentäglich über 12.000 News
Das nächste Lila Sciences? Telescope Innovations ist das 30-Millionen-Dollar-Tor zu KI-gesteuerter Chemie
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von PMLiVE

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
23.07.AstraZeneca unveils plans to boost US footprint with $50bn investment
23.07.Roche's Itovebi granted EC approval to treat advanced breast cancer patients
23.07.NICE recommends ALK's immunotherapy to target underlying cause of hay fever
23.07.FDA appoints George Tidmarsh as director of CDER
22.07.Biogen to boost US manufacturing footprint with $2bn North Carolina investment
22.07.Eli Lilly/Almirall's Ebglyss shows promise in atopic dermatitis patients with darker skin tones
22.07.Sanofi to expand respiratory vaccines pipeline with $1.6bn Vicebio acquisition
21.07.LEO Pharma gains access to Boehringer's skin disease drug for €90m upfront
21.07.AstraZeneca shares late-stage results for Tagrisso combination in lung cancer
21.07.EC approves SpringWorks Therapeutics' Ezmekly to treat rare genetic disorder NF1
18.07.Johnson & Johnson's TAR-200 granted FDA priority review to treat bladder cancer
18.07.NICE recommends BeOne's Brukinsa to treat mantle cell lymphoma on NHS
18.07.Alnylam's Amvuttra approved by MHRA to treat rare heart disease ATTR-CM
17.07.Novartis' Kisqali recommended by NICE to treat broad early breast cancer population
17.07.MHRA approves KalVista Pharmaceuticals' Ekterly to treat hereditary angioedema attacks
17.07.GCI Health announces realignment of European leadership team
16.07.Bayer's Kerendia granted FDA approval for new heart failure indication
16.07.EC approves BeOne Medicines' Tevimbra to treat nasopharyngeal cancer
16.07.Pfizer/Astellas share positive overall survival results for Xtandi in prostate cancer
15.07.AstraZeneca's baxdrostat shows promise in phase 3 hypertension study
15.07.AbbVie gains rights to IGI's phase 1 trispecific engager in deal worth over $1.9bn
15.07.Vertex's triple combination cystic fibrosis therapy Alyftrek recommended by NICE
14.07.Merck to expand respiratory disease portfolio with $10bn Verona Pharma acquisition
14.07.FDA publishes over 200 complete response letters in effort to increase transparency
11.07.Amgen's bemarituzumab shows promise in phase 3 gastric cancer study